Clinical Trial Update: Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial investigating lazertinib in combination with chemotherapy for EGFR-mutant non-small cell lung cancer after incomplete response to lazertinib monot…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lazertinib (lazertinib)

Snippet

Sponsor: Yonsei University | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN